Expo Hub
Liver Disease: Reduce Unnecessary Referrals and Save Healthcare Costs
About this session
To reduce the burden of unnecessary referrals and improve detection of advanced liver disease, a “NAFLD pathway” was developed comprised of testing first with FIB-4 and reflexing indeterminate results to ELF. After 2 years the pathway data was compared to the Standard of Care.1
1 / 0
ELF: The First of its Kind Blood Test for Patients with Advanced Fibrosis due to NASH
Chief Medical Officer, Dr. Chuck Cooper, speaks with Dr. Melanie Pollan, Head of Scientific and Clinical Consulting about the Enhanced Liver Fibrosis (ELF) Test. In this session they will discuss: current challenges in the treatment of NAFLD/NASH and the critical role the laboratory plays in managing these patients.